Full Press Release Details
InspireMD Announces Pricing of Public
BOSTON, MA - March 16, 2016 - InspireMD,
Inc. ("InspireMD" or the "Company") (NYSE MKT: NSPR), a leader in embolic protection systems ("EPS"),
today announced the pricing of an underwritten public offering of 1,900,000 shares of its common stock and warrants to purchase
up to 950,000 shares of common stock (the "Public Offering"). The common stock will be sold at a price of $0.59 per
share, and each purchaser will receive a warrant to purchase one half of one share of common stock for each share of common stock
that it purchases. The warrants shall be exercisable immediately and have a term of exercise of five years from the date of issuance
and an exercise price of $0.59 per full share of common stock. Dawson James Securities, Inc., is serving as the sole bookrunner
for the Public Offering.
The Company expects to receive gross proceeds from the Public
Offering of approximately $1.12 million, before deducting the applicable underwriting discount and estimated offering expenses
payable by the Company.
The Public Offering is expected to close on or about March 21,
2016, subject to customary closing conditions.
The Company intends to use the net proceeds from the Public
Offering to conduct sales activities related to CGuard EPS , and MGuard Prime EPS, and for general corporate
The securities intended to be sold in the Public Offering described
above are being offered pursuant to a shelf registration statement on Form S-3 which was filed with the Securities and Exchange
Commission ("SEC") and was declared effective on November 27, 2013. A preliminary prospectus supplement relating to the
offering was filed with the SEC on March 15, 2016 and a final prospectus supplement relating to the offering will be filed with
the SEC by March 16, 2016. Copies of the prospectus supplement and accompanying prospectus relating to the offering may be obtained
from Dawson James Securities, Inc., Attention: Prospectus Department, 1 North Federal Highway, 5th Floor, Boca Raton, FL 33432,
mmaclaren@dawsonjames.com or toll free at 866.928.0928.
This press release shall not constitute an offer to sell or
the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such
offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state
About InspireMD, Inc.
InspireMD seeks to utilize its proprietary MGuard
with MicroNet technology to make its products the industry standard for embolic protection and to provide a superior solution
to the key clinical issues of current stenting in patients with a high risk of distal embolization, no reflow and major adverse
InspireMD intends to pursue applications of this MicroNet technology
in coronary, carotid (CGuard), neurovascular, and peripheral artery procedures. InspireMD's common stock is quoted on the NYSE
MKT under the ticker symbol NSPR.
Forward-looking Statements
This press release contains "forward-looking
statements." Such statements may be preceded by the words "intends," "may," "will," "plans,"
"expects," "anticipates," "projects," "predicts," "estimates," "aims,"
"believes," "hopes," "potential" or similar words. Forward-looking statements are not guarantees
of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many
of which are beyond the Company's control, and cannot be predicted or quantified and consequently, actual results may differ materially
from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks
and uncertainties associated with (i) market acceptance of our existing and new products, (ii) negative clinical trial results
or lengthy product delays in key markets, (iii) an inability to secure regulatory approvals for the sale of our products, (iv)
intense competition in the medical device industry from much larger, multinational companies, (v) product liability claims, (vi)
product malfunctions, (vii) our limited manufacturing capabilities and reliance on subcontractors for assistance, (viii) insufficient
or inadequate reimbursement by governmental and other third party payers for our products, (ix) our efforts to successfully obtain
and maintain intellectual property protection covering our products, which may not be successful, (x) legislative or regulatory
reform of the healthcare system in both the U.S. and foreign jurisdictions, (xi) our reliance on single suppliers for certain product
components, (xii) the fact that we will need to raise additional capital to meet our business requirements in the future and that
such capital raising may be costly, dilutive or difficult to obtain and (xiii) the fact that we conduct business in multiple foreign
jurisdictions, exposing us to foreign currency exchange rate fluctuations, logistical and communications challenges, burdens and
costs of compliance with foreign laws and political and economic instability in each jurisdiction. More detailed information about
the Company and the risk factors that may affect the realization of forward looking statements is set forth in the Company's filings
with the Securities and Exchange Commission (SEC), including the Company's Annual Report on Form 10-K and its Quarterly Reports
on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC's web site at http://www.sec.gov.
The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future
events or otherwise.
Chief Financial Officer
Phone: 1-888-776-6804
Email: craigs@inspiremd.com